Presentation is loading. Please wait.

Presentation is loading. Please wait.

Group 4 Gaps & obstacles.

Similar presentations


Presentation on theme: "Group 4 Gaps & obstacles."— Presentation transcript:

1 Group 4 Gaps & obstacles

2 How do we better utilize what we already have
How do we better utilize what we already have? Anything that simplifies will help Outcomes research of current practice e.g. Where adult FDC already in use in children Approximation of doses to accommodate solid formulations

3 Research needs (1) pK Simplified dosing regimens Age
Mg/kg versus BSA Rounding off of doses Use of adult formulations Age Nutritional status Include the effect of changing status on dosage e.g. marasmic infant Genetics

4 Research needs (2) pK (continued) Specific drug-related questions ddI
Daily vs bid Food with admin 2 tablets for buffering? NVP & 3TC Clarify dose EFV < 3y or 10kg

5 Longitudinal outcome cohorts in resource-constrained settings “Post marketing surveillance”
Adherence in children What is the best approach What intensity? Systems for surveillance Clinical outcome Resistance Toxicity Program evaluation

6 PMTCT interventions FDCs must reflect resistance concerns
Mother & infant


Download ppt "Group 4 Gaps & obstacles."

Similar presentations


Ads by Google